ARTICLE | Clinical News
GBT-201: Phase IIb/III started
September 28, 2015 7:00 AM UTC
ReGenTree LLC began a double-blind, placebo-controlled Phase IIb/III trial to evaluate topical RGN-259 given 4 times daily for 28 days in about 350 patients. ReGenTree, a JV between RegeneRx and G-tre...